Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
20 05 2021
Historique:
received: 13 04 2021
revised: 13 05 2021
accepted: 18 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 29 6 2021
Statut: epublish

Résumé

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.

Identifiants

pubmed: 34065213
pii: ijerph18105457
doi: 10.3390/ijerph18105457
pmc: PMC8160774
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Oncol. 2012 Aug;23(8):2128-2137
pubmed: 22241896
BMJ Open. 2018 Mar 9;8(3):e020574
pubmed: 29525772
JAMA Intern Med. 2019 Apr 1;179(4):490-498
pubmed: 30742202
Am J Clin Nutr. 2016 Nov;104(5):1433-1440
pubmed: 27733404
Haematologica. 2018 Nov;103(11):1881-1888
pubmed: 29954942
Eur J Cancer. 2007 Jul;43(11):1731-40
pubmed: 17596928
Eur J Clin Nutr. 1997 Oct;51(10):708-12
pubmed: 9347293
Public Health Nutr. 2014 Jul;17(7):1531-7
pubmed: 23659580
Leuk Lymphoma. 2018 Feb;59(2):434-447
pubmed: 28847196
Nutrients. 2016 Feb 27;8(3):120
pubmed: 26927171
BMJ. 2018 Feb 14;360:k322
pubmed: 29444771
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
Int J Behav Nutr Phys Act. 2015 Dec 18;12:160
pubmed: 26684833
Public Health Nutr. 2018 Jan;21(1):1-4
pubmed: 29227217
Int J Cancer. 2018 Aug 1;143(3):486-495
pubmed: 29460427
BMJ. 2019 May 29;365:l1949
pubmed: 31142450
Ann Oncol. 1998 Jul;9(7):717-20
pubmed: 9739436
Clin Nutr. 2021 Apr;40(4):1537-1545
pubmed: 33743289
Mayo Clin Proc. 2019 Nov;94(11):2178-2188
pubmed: 31623843
BMJ. 2019 May 29;365:l2289
pubmed: 31142449
Exp Hematol Oncol. 2020 Jun 19;9:14
pubmed: 32577323
Nutr Cancer. 2018 Aug-Sep;70(6):821-839
pubmed: 30288994
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1064-77
pubmed: 21493873
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):41-51
pubmed: 25174025
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
Public Health Nutr. 2018 Jan;21(1):18-26
pubmed: 28714422
Public Health Nutr. 2018 Jan;21(1):27-37
pubmed: 28703085
Am J Clin Nutr. 2015 Jun;101(6):1251-62
pubmed: 25948666
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Crit Rev Oncol Hematol. 2016 Apr;100:16-24
pubmed: 26921971
BMJ. 2019 May 29;365:l1451
pubmed: 31142457

Auteurs

Marta Solans (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17003 Girona, Spain.

Sílvia Fernández-Barrés (S)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08036 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.

Dora Romaguera (D)

ISGlobal, 08036 Barcelona, Spain.
Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases, 07120 Palma de Mallorca, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28001 Madrid, Spain.

Yolanda Benavente (Y)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.

Rafael Marcos-Gragera (R)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17003 Girona, Spain.
Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, 17007 Girona, Spain.
Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain.

Esther Gracia-Lavedan (E)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08036 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.

Laura Costas (L)

Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.

Claudia Robles (C)

Unit of Information and Interventions in Infections and Cancer (UNIC-I&I), Cancer Epidemiology Research Programme, (IDIBELL), Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.

Eva Gonzalez-Barca (E)

Hematology, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.

Esmeralda de la Banda (E)

Hematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, 08908 L'Hospitalet de Llobregat, Spain.

Esther Alonso (E)

Hematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, 08908 L'Hospitalet de Llobregat, Spain.

Marta Aymerich (M)

Hematopathology Section, Hospital Clinic de Barcelona, University of Barcelona, CIBERONC, 08001 Barcelona, Spain.

Elias Campo (E)

Hematopathology Section, Hospital Clinic de Barcelona, University of Barcelona, CIBERONC, 08001 Barcelona, Spain.

Javier Llorca (J)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Faculty of Medicine, University of Cantabria-IDIVAL, 39011 Santander, Spain.

Guillermo Fernández-Tardón (G)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, 33003 Oviedo, Spain.

Rocío Olmedo-Requena (R)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, 18071 Granada, Spain.
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.

Eva Gimeno (E)

Hematology Department, Hospital del Mar, 08003 Barcelona, Spain.

Gemma Castaño-Vinyals (G)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08036 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), 08001 Barcelona, Spain.

Nuria Aragonés (N)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Epidemiology Section, Public Health Division, Department of Health, 28009 Madrid, Spain.

Manolis Kogevinas (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08036 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), 08001 Barcelona, Spain.

Marina Pollán (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Cancer Epidemiology Unit, National Centre for Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Silvia de Sanjose (S)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.
Sexual and Reproductive Health, PATH, Seattle, WA 98121, USA.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, 20013 San Sebastián, Spain.
Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, 20014 San Sebastián, Spain.

Delphine Casabonne (D)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 L'Hospitalet de Llobregat, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH